en · de · es · fr · pt
faq-desk.peptides6155.com › Info › Background And Receptor Mechanism — Questions and Answers

Background And Receptor Mechanism — Questions and Answers

By Editorial Desk · published 2026-06-08 · last reviewed 2026-07-18 · Info

research compound is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-07-18. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Related pages on this site

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Notes from published material

In August 2008, Obama and Biden met in secret to discuss the possibility of a place for Biden in the Obama administration, and developed a strong personal rapport. On August 22, Obama announced that Biden would be his running mate. The New York Times reported that the choice reflected a desire for someone with foreign policy and national security experience. Others pointed out Biden's appeal to middle-class and blue-collar voters. Biden was officially nominated for vice president on August 27 at the 2008 Democratic National Convention in Denver. Biden's vice-presidential campaigning gained little media attention, as the press devoted far more coverage to the Republican nominee and then-governor of Alaska, Sarah Palin. Under instructions from the campaign, Biden kept his speeches succinct and tried to avoid offhand remarks. Privately, Biden's remarks frustrated Obama. "How many times is Biden gonna say something stupid?", he once angrily asked. Obama campaign staffers called Biden's blunders "Joe bombs" and kept Biden uninformed about strategy discussions, which irked Biden. Relations between the two campaigns became strained for a month, until Biden apologized to Obama and the two built a stronger partnership. As the 2008 financial crisis reached a peak in September 2008, and the proposed Emergency Economic Stabilization Act of 2008 became a major factor in the campaign, Biden voted for the $700 billion Emergency Economic Stabilization Act of 2008, which passed in the Senate.

== Description == Most cases of feline hypersomatotropism are caused by acidophilic pituitary tumours that predominantly secrete growth hormone. In some cases low levels of other pituitary hormones are secreted. Rarely a cat may have double adenomas. In a few cases the diagnosis has been pituitary acidophilic hyperplasia. In dogs nearly all cases of acromegaly are caused by endogenous or exogenous progestogens, this causes a hypersecretion of growth hormones from the mammary gland. Pituitary tumours causing excess growth hormone secretion are very rare in dogs.

== History == Guzman y Gomez was established by Steven Marks, a New Yorker who previously worked as a hedge fund manager. After relocating to Australia, he found the quality of Mexican food to be poor and decided to start a restaurant. He has stated that "real Mexican is really urban, street and hot [...] Latin people are so full of energy and full of life, we wanted to bring that to Australia". He took on his friend Robert Hazan, another New Yorker, as a partner. They named the business after two of Marks' childhood friends. The first store was opened in King Street, Newtown, Sydney, in 2006. Store openings in Bondi Junction and Kings Cross, followed within a year. By April 2012, there were 12 stores. The first Guzman y Gomez in the Melbourne central business district opened in November 2012. Within 12 years, they opened 100 stores in Australia. The first international Guzman y Gomez restaurant opened at the end of 2013 in Singapore, followed thereafter by the opening of a restaurant in Tokyo, Japan, in April 2015. In January 2020, Guzman y Gomez's international expansion continued with the opening of their first restaurant in the United States in the Chicago suburb of Naperville. In May 2026, Guzman y Gomez announced the closure of all of their restaurants in the United States.

Sources: en.wikipedia.org

Background from the literature

It can be difficult to tell whether a trait has been lost and then re-evolved convergently, or whether a gene has simply been switched off and then re-enabled later. Such a re-emerged trait is called an atavism. From a mathematical standpoint, an unused gene (selectively neutral) has a steadily decreasing probability of retaining potential functionality over time. The time scale of this process varies greatly in different phylogenies; in mammals and birds, there is a reasonable probability of a gene's remaining in the genome in a potentially functional state for around 6 million years.

=== Early guerrilla incursions === In November 1960, Ethiopia and Liberia had formally petitioned the ICJ for a binding judgment, rather than an advisory opinion, on whether South Africa remained fit to govern South West Africa. Both nations emphasised that they considered the implementation of apartheid to be a violation of Pretoria's obligations as a mandatory power. The National Party government rejected the claim on the grounds that Ethiopia and Liberia lacked sufficient legal interest to present a case concerning South West Africa. This argument suffered a major setback on 21 December 1962 when the ICJ ruled that, as former League of Nations member states, both parties had a right to institute the proceedings. Around March 1962, SWAPO President Sam Nujoma visited the party's refugee camps across Tanzania, describing his recent petitions for South West African independence at the Non-Aligned Movement and the UN. He pointed out that independence was unlikely in the foreseeable future, predicting a "long and bitter struggle". Nujoma personally directed two exiles in Dar es Salaam, Lucas Pohamba and Elia Muatale, to return to South West Africa, infiltrate Ovamboland and send back more potential recruits for SWALA. Over the next few years, Pohamba and Muatale successfully recruited hundreds of volunteers from the Ovamboland countryside, most of whom were shipped to Eastern Europe for guerrilla training. Between July 1962 and October 1963 SWAPO negotiated military alliances with other anti-colonial movements, namely in Angola.

The Census and Statistics Department estimated Hong Kong's population at 7,413,070 in 2021. The overwhelming majority (91.6%) is Chinese, most of whom are Taishanese, Teochew, Hakka, and other Cantonese peoples. The remaining 8.4% are non-ethnic Chinese minorities, primarily Filipinos, Indonesians, and South Asians. However, most Filipinos and Indonesians in Hong Kong are short-term workers. According to a 2021 thematic report by the Hong Kong government, after excluding foreign domestic helpers, the real number of non-Chinese ethnic minorities in the city was 301,344, or 4% of Hong Kong's population. About half the population have some form of British nationality, a legacy of colonial rule; 3.4 million residents have British National (Overseas) status, and 260,000 British citizens live in the territory. The vast majority also hold Chinese nationality, automatically granted to all ethnic Chinese residents at the handover. Headline population density exceeds 7,060 people/km2 It is the fourth-highest in the world.

Sources: en.wikipedia.org

Further detail

president Edward Boling, Mayor Randy Tyree (Testerman's successor), Pilot president Jim Haslam, Knoxville Superintendent of Schools Mildred Doyle, and Knox County judge Howard Bozeman, the initiative again failed. While a majority of Knoxvillians had voted in favor of consolidated government, a majority of Knox Countians had voted against it.

=== In drug discovery and biomedical research === The ability to grow up functional adult tissues indefinitely in culture through Directed differentiation creates new opportunities for drug research. Researchers are able to grow up differentiated cell lines and then test new drugs on each cell type to examine possible interactions in vitro before performing in vivo studies. This is critical in the development of drugs for use in veterinary research because of the possibilities of species-specific interactions. The hope is that having these cell lines available for research use will reduce the need for research animals used because effects on human tissue in vitro will provide insight not normally known before the animal testing phase.

Although the anti-American films were notably popular with audiences, the Ministry did not feel the message had reached the general public, perhaps due to the fact that the majority of moviegoers seeing the films produced were, perhaps, the Soviets most likely to admire American culture. After Stalin's death, a Main Administration of Cinema Affairs replaced the Ministry, allowing the filmmakers more freedom due to the lack of direct government control. Many of the films released throughout the late 1950s and 1960s focused on spreading a positive image of Soviet life, intent to prove that Soviet life was indeed better than American life. Russian science fiction emerged from a prolonged period of censorship in 1957, opened up by de-Stalinization and real Soviet achievements in the space race, typified by Ivan Efremov's galactic epic, Andromeda (1957). Official Communist science fiction transposed the laws of historical materialism to the future, scorning Western nihilistic writings and predicting a peaceful transition to universal communism. Scientocratic visions of the future nevertheless implicitly critiqued the bureaucratically developed socialism of the present. Dissident science fiction writers emerged, such as the Strugatski brothers, Boris and Arkadi, with their "social fantasies," problematizing the role of intervention in the historical process, or Stanislaw Lem's tongue-in-cheek exposures of man's cognitive limitations.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

Network